Veeco launches Lumina+ MOCVD system, receives Rocket Lab order
REDWOOD CITY, Calif. - Revolution Medicines, Inc. (NASDAQ:RVMD), an $8.2 billion market cap oncology company currently trading near its InvestingPro Fair Value, announced Monday the appointment of Alan Sandler, M.D. as chief development officer, a newly created role at the late-stage clinical oncology company.
The company, which focuses on developing targeted therapies for RAS-addicted cancers, also appointed regional general managers for the U.S. and European markets as it builds its global commercial capabilities. According to InvestingPro data, the company maintains strong financial flexibility with a current ratio of 11.79 and more cash than debt on its balance sheet.
Dr. Sandler joins Revolution Medicines from ALX Oncology, where he served as chief medical officer. His previous experience includes executive roles at Mirati Therapeutics, Zai Lab Limited, and Genentech. He has held academic leadership positions in thoracic oncology at several universities.
The company has also appointed Alicia Gardner as senior vice president and general manager for the U.S. region, and Gerwin Winter as senior vice president and general manager for the European region.
These appointments come as Revolution Medicines prepares for potential approvals and commercial launches of daraxonrasib for RAS-driven cancers, including pancreatic ductal adenocarcinoma.
"I am delighted to welcome Alan as our chief development officer as we pursue our bold vision to develop new global standards of care for patients with RAS-addicted cancers," said Mark A. Goldsmith, M.D., Ph.D., chief executive officer and chairman of Revolution Medicines, in a press release statement.
Revolution Medicines’ pipeline includes several RAS(ON) inhibitors currently in clinical development: daraxonrasib, elironrasib, and zoldonrasib. The company anticipates that RMC-5127 will be its next RAS(ON) inhibitor to enter clinical development. With analysts setting price targets as high as $99 and maintaining a strong buy consensus, InvestingPro subscribers can access detailed analysis and 8 additional ProTips about the company’s financial health and growth prospects.
In other recent news, Revolution Medicines reported promising clinical data for its experimental cancer drug, daraxonrasib, in treating metastatic pancreatic ductal adenocarcinoma. The long-term follow-up data revealed a confirmed objective response rate of 29% and disease control in 95% of patients, with median progression-free survival at 8.1 months and median overall survival reaching 15.6 months. Needham responded to these results by raising its price target for Revolution to $66, maintaining a Buy rating, as the company plans to initiate its RASolute 303 Phase 3 trial in the fourth quarter of 2025. Additionally, Raymond James assumed coverage on Revolution with a Strong Buy rating and a price target of $72, citing the broad activity of daraxonrasib. Truist Securities also initiated coverage with a Buy rating and a $99 price target, emphasizing Revolution’s focus on targeting RAS mutations. Meanwhile, Oppenheimer reiterated its Outperform rating and $75 price target, noting the company’s progress in enrolling patients for the daraxonrasib RASolute-302 study, with initial data expected in 2026.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.